Skip to main content
Sopharma AD logo

Sopharma AD — Investor Relations & Filings

Ticker · SFA ISIN · BG11SOSOBT18 LEI · 097900BGGW0000048796 BSOBGN Manufacturing
Open in API
Filings indexed 1,480 across all filing types
Latest filing 2025-06-06 Director's Dealing
Country BG Bulgaria
Listing BSOBGN SFA

About Sopharma AD

https://www.sopharmagroup.com/

Sopharma AD is a pharmaceutical company founded in 1933 that specializes in the production, distribution, and export of a wide range of medical products. The company's portfolio includes prescription (Rx) and over-the-counter (OTC) medicines, encompassing both branded and generic drugs. A key area of focus is its traditional plant-based products. Sopharma develops treatments for various conditions, including liver disease, pain management, and smoking cessation. Operating from EU-GMP certified facilities, the company also provides contract manufacturing services and has an established presence in over 40 international markets.

Recent filings

Filing Released Lang Actions
Notification from Ognian Donev in accordance with Regulation 596/2014 for transactions with shares of "Sopharma" AD
Director's Dealing Classification · 100% confidence The document text clearly details a transaction report concerning an individual ('Ognian Ivanov Donev') who is a person discharging managerial responsibilities (Executive director and Chairman of the Board of directors) at the issuer ('Sopharma AD'). The content explicitly lists the nature of the transaction ('Buy'), the financial instrument (Shares, ISIN № BG11SOSOBT18), and the aggregated price and volume details. This structure perfectly matches the definition of a Director's Dealing report, which tracks personal share transactions by company directors and executives.
2025-06-06 English
Notification of sale of treasury shares
Transaction in Own Shares Classification · 100% confidence The document is a 'Current report' dated June 6, 2025, specifically detailing a transaction involving 'Treasury shares'. It explicitly states that the Company 'sold 13 660 (thirteen thousand six hundred and sixty) repurchased own shares'. This action directly corresponds to the definition of a company buying back or selling its own shares, which maps precisely to the 'Transaction in Own Shares' category.
2025-06-06 English
Individual financial report according to IFRS as at 31 March 2024
Regulatory Filings Classification · 19% confidence
2024-04-30 Polish
Publication of Annual consolidated audited financial report of "Sopharma" AD for 2023 in ESF format
Annual Report Classification · 100% confidence The document is titled 'Consolidated Annual Financial Statements for Year 2023' and contains detailed financial statements including the statement of comprehensive income, statement of financial position, statement of cash flows, statement of changes in equity, and extensive notes to the consolidated financial statements. It covers the full fiscal year 2023 and includes management report, corporate governance declaration, non-financial declaration, declaration by responsible persons, auditors' report, and auditors' declaration. The document length is substantial (15,000 characters), indicating it is the full report rather than an announcement or summary. The presence of comprehensive financial data and notes confirms it is the official annual report. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-04-25 Polish
610654-SFA_Annual_cons_financial_statements_2023_EN.pdf
Audit Report / Information Classification · 98% confidence The document is very short (1772 characters) and its primary function is to announce the availability of the 'Annual Audited Consolidated Financial Statements of "Sopharma" AD as at 31 December 2023'. It explicitly states that the report is being presented and provides links to where the full information (including the financial statements, management report, and audit report) can be found. This fits the definition of a Report Publication Announcement (RPA), as it is announcing the publication of the full reports rather than being the report itself (which would typically be much longer, like a 10-K or IR). FY 2023
2024-04-24 English
610652-097900BGGW0000048796-20231231-EN-CON.zip
Annual Report Classification · 100% confidence The document contains detailed consolidated annual financial statements for the year 2023, including comprehensive income, financial position, cash flows, and changes in equity. It includes extensive financial data, notes references, and covers a full fiscal year. The length is substantial (15,000 characters), and the content is consistent with a full annual report rather than a summary or announcement. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2023
2024-04-24 Bulgarian

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.